Clinical trials recruiting in Cangzhou, China

Phase breakdown

Conditions recruiting in Cangzhou, China

Recruiting trials in Cangzhou, China

• A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
  NCT07043725 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
  NCT07406035 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
  NCT07367529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
  NCT07253142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
  NCT07797335 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female)
• Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
  NCT07161388 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
  NCT06569524 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
  NCT07516184 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  NCT07304739 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
  NCT06416410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
  NCT07416474 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Smartwatch-based Intervention for Cardiovascular Health (SWITCH)
  NCT07372729 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
  NCT07058948 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
  NCT04930432 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
  NCT06534658 · Phase: Not specified · Ages: 50 Years to 85 Years · Sex: All (male and female)
• TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
  NCT06829784 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Cangzhou, China?

19 recruiting trials have at least one study site in Cangzhou, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.